Clinical Treatment Options for Carbapenem-resistant Gram-negative Infections in China: a Single Centre Real-world Experience

Ruanmei Sheng
Shanghai Jiaotong University: Shanghai Jiao Tong University

Xuemin Wang
Shanghai Jiao Tong University

Yanqiang Hou
Shanghai Jiao Tong University

Jun Liu
Shanghai Jiao Tong University

Zhiwen Yang (yangzhiwen2009@sina.com)
Shanghai Jiaotong University

Research

Keywords: antibiotic options, single centre, CRKP, CRPA, CRAB

DOI: https://doi.org/10.21203/rs.3.rs-731712/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Carbapenem-resistant gram-negative bacteria constitute a serious threat to public health worldwide. However, as a result of the complexities of clinical therapy, antibiotic options against carbapenem-resistant pathogens have not yet been fully standardized. Here, we conducted a retrospective study in 65,000 inpatients over a 2-year period that involved a total of 86 patients from whom carbapenem-resistant gram-negative bacteria were isolated. Monotherapy using trimethoprim/sulfamethoxazole, amikacin, meropenem, and/or doxycycline in our hospital exhibited a clinical success rate of 83.3% for carbapenem-resistant *Klebsiella pneumoniae*, monotherapy using moxifloxacin, piperacillin/tazobactam, cefepime, and/or ceftazidime for carbapenem-resistant *Pseudomonas aeruginosa* exhibited a clinical success rate of 77.7%, and monotherapy using cefoperazone/sulbactam or combination therapy with tigecycline and cefoperazone/sulbactam for carbapenem-resistant *Acinetobacter baumannii* exhibited a clinical success rate of 62.1%. Our findings highlight the clinical strategies used in our hospital to successfully treat carbapenem-resistant gram-negative bacterial infections.

Introduction

Carbapenem-resistant gram-negative bacteria have become increasingly prevalent in recent years, and now constitute a serious threat to public health worldwide. The antibiotic-resistant phenotype of these bacteria leads to more severe clinical outcomes and an increased economic burden because of greater medical costs, longer hospital stays, the need for intensive care units, and increased mortality. In general, carbapenem-resistant gram-negative bacteria include carbapenem-resistant *Klebsiella pneumoniae (CRKP)*, carbapenem-resistant *Pseudomonas aeruginosa (CRPA)*, and carbapenem-resistant *Acinetobacter baumannii (CRAB)*. CRKP were found in 3.2–7.1% of outpatients, CRPA ranged from 6.6–9.8% of patients on regular wards, and CRAB occurred in 11.5–13.4% of patients in intensive care units [1].

In clinical practice, carbapenem has been identified as a better choice for the systemic treatment of serious gram-negative bacterial infections. Given the high frequency of antibiotic resistance, carbapenem resistance poses a new and difficult challenge in therapeutic decision-making [2]. To date, several retrospective studies have been reported that consider treatment options for carbapenem-resistant gram-negative bacterial infections, and some guidance has been recommended for clinical practice [1, 3, 4]. However, as a result of the complexities of clinical infections, antibiotic therapy needs to be individualized to control carbapenem-resistant pathogens in accordance with different regions [5–8].

In this study, we focused on our hospital’s own strategy for treating bacterial infections and tried to identify optimal antibiotic therapeutic strategies to improve clinical efficacy when treating carbapenem-resistant pathogens.

Methods
Study setting

The study was performed at the Songjiang Hospital affiliated to Shanghai Jiao Tong University School of Medicine (Preparatory Stage), the only regional medical centre in Songjiang district of Shanghai, comprising 1035 beds for a population of 2 million people. It is a tertiary facility with up to 3.7 million outpatients and emergency patients, 65,000 inpatients, and 43,000 surgical patients from 2018 to 2019.

Patients

We conducted a retrospective cohort study during the period from January 2018 to December 2019. All patients with clinically-isolated carbapenem-resistant gram-negative bacteria in our hospital were included in the study. A total of 86 consecutive patients were assayed for carbapenem-resistant gram-negative bacteria, of which 44 were infected and 42 were colonized with this organism. Patients were excluded if they tested positive for colonization.

According to the standards of the United States Centers for Diseases Control and Prevention [9], we assayed for healthcare-associated infections and colonization. Briefly, bacterial colonization was defined as a positive culture from a patient without any clinical symptoms of infection, while bacterial infection was characterized by a positive culture from a patient with signs of inflammation. Infectious indices generally refer to body temperature, white blood cell (WBC) count, and C-reactive protein (CRP) and procalcitonin (PCT) levels. Carbapenem-resistant gram-negative bacteria isolated from patients were resistant to both meropenem and imipenem.

The studies involving human participants were reviewed and approved by the research committee of Shanghai Songjiang Clinical Medical College of Nanjing Medical University. The patients/participants provided written informed consent to participate in this study.

Evaluation of therapeutic efficiency

Global cure was a composite endpoint, which was defined as clinical improvement and microbiological clearance by day 7. Clinical improvement was deemed as being afebrile for ≥ 48h, having less than 12,000 cells/mm³ or a ≥25% reduction in the WBC count, and being hemodynamically stable without the need for vasopressors. Microbiological clearance referred to eradication of the original causative organism from subsequent bacterial cultures upon 7-day therapy, whereas microbiological failure referred to persistence of the original causative organism in the subsequent bacterial cultures by day 7. In the absence of follow-up bacterial culture data, patients who showed clinical improvement were defined as displaying microbiological clearance [10].

Bacterial isolation

Clinical specimens were collected for bacterial culture on or after day 3 of hospitalization. Antimicrobial susceptibility data were obtained before patients received antimicrobial therapy for carbapenem-resistant gram-negative bacteria.
Multiple drug resistant (MDR) refers to the absence of susceptibility to three or more antimicrobial categories. Extensively drug resistant (XDR) refers to the absence of susceptibility to all but two or fewer antimicrobial categories. Pan-drug resistant (PDR) refers to the absence of susceptibility to all antimicrobial categories.

**Results**

**Clinical therapy and the outcome of CRKP infection**

Among 12 patients for whom CRKP was detected, six were defined as colonization and six were defined as infection. Of note, the infectious indices, which included the WBC count, CRP and PCT levels, from six patients with CRKP were significantly elevated (Supplementary Table 1). The in vitro antibiotic susceptibility data against CRKP infection were summarized in Table 1 and Supplementary Table 2. CRKP was resistant to meropenem and imipenem, but highly susceptible to tigecycline, amikacin, and trimethoprim/sulfamethoxazole, with sensitivity rates of 100%, 83.3%, and 50.0%, respectively.

Consistent with our antibiotic susceptibility profile, antibiotic monotherapy in our hospital showed a success rate of 83.3% (5/6) for eliminating CRKP, only one case of a urinary tract infection failed treatment with moxifloxacin (Table 2). Five patients were successfully treated with monotherapy, two (one urinary tract and one lung infection) with trimethoprim/sulfamethoxazole, one (lung infection) with doxycycline, one (urinary tract infection) with amikacin, and one (lung infection) with meropenem, which was indicative of a positive clinical outcome. Interestingly, meropenem resistance was established for CRKP in vitro, but it showed a better clinical outcome for patients. Taken together, monotherapy with trimethoprim/sulfamethoxazole, amikacin, meropenem and/or doxycycline served as the effective therapeutic strategy for CRKP in our hospital.

**Clinical therapy and the outcome of CRPA infection**

Among 13 patients for whom CRPA was detected, four were defined as colonization and nine were defined as infection. As presented in Supplementary Table 3, the infectious indices for nine patients with CRPA were significantly elevated. To evaluate the success of antibiotic therapy, we determined the susceptibility rates of these bacteria to antibiotics in vitro (Table 3 and Supplementary Table 4). CRPA showed resistance to meropenem and imipenem, but was relatively sensitive to cefepime, piperacillin/tazobactam, and ceftazidime at rates of 88.9%, 66.7%, and 66.7%, respectively.

The clinical outcomes exhibited a high success rate (7/9, 77.7%) for eliminating CRPA (Table 4). Of the two cases with lung infection for whom treatment failed, one patient was treated with ceftazidime monotherapy and one patient was treated with moxifloxacin and meropenem combination therapy. As a result of their transfer to another hospital, they did not receive the alternative antimicrobial therapy. Among the seven cases that were successfully treated, five patients with a lung infection received therapy with either moxifloxacin (n = 2), piperacillin/tazobactam (n = 2), or ceftazidime (n = 1), and one patient with a urinary tract infection received cefepime monotherapy and one patient with a blood infection...
received moxifloxacin monotherapy. Of note, one patient experienced a significant improvement in respiratory symptoms, with initial failure to moxisaxin therapy, followed by ceftazidime administration. Taken together, antibiotic monotherapy with moxifloxacin, piperacillin/tazobactam, cefepime, and ceftazidime exhibited good clinical efficacy against CRPA in accordance with our antibiotic susceptibility test.

Clinical therapy and the outcome of CRAB infection

Among 61 patients for whom CRAB was detected, 32 were defined as colonization and 29 were defined as infection. As presented in Supplementary Table 5, the infectious indices for 29 patients with CRAB were significantly elevated. As presented in Table 5 and Supplementary Table 6, CRAB exhibited resistance to meropenem and imipenem, but was relatively sensitive to tigecycline (89.6%), cefoperazone/sulbactam (55.1%), and piperacillin/tazobactam (33.5%).

The clinical outcomes exhibited a relatively high success rate (18/29, 62.1%) for eliminating CRAB infection upon monotherapy or combination therapy (Table 6). First, monotherapy was administered to 19 patients. Of the twelve patients who received cefoperazone/sulbactam monotherapy, nine (eight lung and one blood infection) showed clinical improvement and three (two lung and one urinary tract infection) showed clinical failure. Of the four patients who received piperacillin/tazobactam monotherapy, two (lung infection) showed clinical improvement and two (lung infection) showed clinical failure. One patient (lung infection) was treated with imipenem/cilastatin monotherapy and showed clinical improvement. Two patients (lung infection) were treated with trimethoprim/sulfamethoxazole and/or meropenem monotherapy and showed no clinical improvement. Second, combination therapy was administered to 10 patients. Of the six patients who received cefoperazone/sulbactam and tigecycline combination therapy, three (two lung and one abdominal cavity infection) showed clinical improvement and three (lung infection) showed clinical failure. Of the two patients who received imipenem/cilastatin and tigecycline combination therapy, one (lung infection) showed clinical improvement and one (lung infection) showed clinical failure. One patient treated for a lung infection with meropenem and tigecycline combination therapy and one patient treated for a urinary tract infection with trimethoprim/sulfamethoxazole and levofloxacin showed clinical improvement. Taken together, cefoperazone/sulbactam monotherapy, or combination therapy with cefoperazone/sulbactam and tigecycline, were the better treatment options for CRAB in our hospital.

Discussion

Our aim was to identify treatment regimens for infections caused by carbapenem-resistant gram-negative bacteria in our hospital. In this study, a total of 44 patients who infected with carbapenem-resistant gram-negative were found in 65,000 inpatients over a 2-year period, indicative of a very low infectious rate. Furthermore, monotherapy (trimethoprim/sulfamethoxazole, amikacin, meropenem, and doxycycline) was an effective antibiotic regimen for the treatment of CRKP infection; monotherapy of moxifloxacin, piperacillin/tazobactam, cefepime, and ceftazidime was the preferred antibiotic choice for CRPA
infection; and cefoperazone/sulbactam monotherapy or tigecycline combination therapy could effectively treat \textit{CRAB} infections.

Carbapenem is the treatment option for patients who develop serious infections with MDR, XDR, and PDR gram-negative bacilli, but unfortunately the resistance to carbapenem significantly compromises this treatment choice \cite{14}. Consequently, carbapenem resistance among gram-negative bacteria is disseminating worldwide, which poses a serious threat to current medical practices. Similar to previous reports \cite{12, 13}, \textit{CRAB} isolates in our study were XDR strains, showing susceptibility to only one and/or two antibiotics \textit{in vitro}. Unlike previous reports \cite{12, 13}, \textit{CRKP} and \textit{CRPA} isolates in our study were MDR, indicative of a better antibiotic choice \textit{in vitro}.

In fact, the antibiotic susceptibility determined by \textit{in vitro} culture does not always correlate with the success of clinical therapy \textit{in vivo} \cite{11}. Exact antibiotic doses and bacterial inocula can be easily assessed on agar plates, but this may not be replicated in patients. As a result, despite many \textit{in vitro} studies of bacterial infection, the findings do not always translate into successful treatment in clinical studies. In this study, we observed that the implementation of antibiotic regimens in \textit{CRKP} and \textit{CRPA}-infected patients were consistent with \textit{in vitro} activity. However, a minor difference was found in \textit{CRAB}-infected patients. Of the 29 patients with \textit{CRAB}, resistance to empirical antibiotics piperacillin/tazobactam (2/2, 100%) and imipenem/cilastatin (1/1, 100%) was shown \textit{in vitro} but patients effectively recovered, and in 20 cases resistance to cefoperazone/sulbactam was shown but clinical efficacy was evident for most patients. This discrepancy maybe attributed to the different environments \textit{in vivo} and \textit{in vitro}, the minimum inhibitory concentrations, as well as the clinical efficacy of the cefoperazone/sulbactam combination \cite{14, 15}.

Current guidance for the treatment of carbapenem-resistant gram-negative bacterial infections relies on antibiotic therapy based on polymyxins (including colistin or polymyxin B), aminoglycosides, and tigecycline \cite{16, 17}. Emerging retrospective clinical studies show that antibiotic options have not yet been fully standardized, and that treatments may need to be individualized to control carbapenem-resistant pathogens depending on different regions \cite{1}. Papst \textit{et al.} showed that in Israel, monotherapy was the preferred choice for treating \textit{CRPA} and \textit{CRAB} infections, whereas in all other countries, combination therapy with two drugs was standard \cite{11}. Ceftazidime/avibactam was commonly used for the treatment of \textit{CRKP}-infected patients in the USA, whereas ceftolozane/tazobactam was often used in Spain, Italy, France, and the USA \cite{11}. Chen \textit{et al.} reported that both monotherapy of colistin and combination therapy of colistin and carbapenem showed high cure rates of \textit{CRAB} and \textit{CRKP} \cite{18}. Our study showed that our hospital’s antibiotic treatment strategies, which included monotherapy of trimethoprim/sulfamethoxazole, amikacin, meropenem, and/or doxycycline therapy for \textit{CRKP}, monotherapy of moxifloxacin, piperacillin/tazobactam, cefepime, and/or ceftazidime for \textit{CRKP}, and monotherapy of cefoperazone/sulbactam or combination therapy with cefoperazone/sulbactam and tigecycline for \textit{CRAB}, according to standard guidance, led to a high cure rate.
Carbapenem resistance mechanisms are most commonly associated with carbapenemase production, porin loss, drug efflux, and target alteration [19]. In China, KPC-2 and NDM gene were identified as the main resistance mechanism of CRKP to carbapenem [20, 21]. Han et al reported that the carbapenemase gene among CRKP were KPC-2 (64.6%, 457/709), NDM (21.1%, 150/709) and OXA-232 (9.3%, 66/709), while only 9 strains were positive for multiple carbapenemases [21]. Additionally, carbapenem-resistance gene OXA-23 played a critical role in carbapenem-resistance of CRAB [22], and metallo-β-lactamase IMP-45 may contribute to CRPA resistance to carbapenem [23, 24].

In summary, our study collates the successful treatment regimens for infections caused by carbapenem-resistant gram-negative bacteria in our hospital. In the future, it will be of great interest to elucidate the molecular mechanisms of carbapenem resistance. It will also be important to further identify optimal antibiotic treatment strategies through a multi-centre study involving a greater number of patients in Shanghai.

Declarations

Acknowledgements

Our profound admiration and respect goes out to the researchers in this field and in our laboratories for their dedication and hard work.

Author contributions

Z.Y. designed the study. R.S., X.W., Y.H., and J. L. analysed data and wrote the manuscript. All authors reviewed the manuscript.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Y. Doi, Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 69 (2019) S565-S575.
2. A.J. Brink, Epidemiology of carbapenem-resistant Gram-negative infections globally, Current opinion in infectious diseases, 32 (2019) 609-616.
3. M. Fritzenwanker, C. Imirzalioglu, S. Herold, F.M. Wagenlehner, K.P. Zimmer, T. Chakraborty, Treatment Options for Carbapenem-Resistant Gram-Negative Infections, Deutsches Arzteblatt international, 115 (2018) 345-352.
4. L. Onorato, G. Di Caprio, S. Signoriello, N. Coppola, Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis, International journal of antimicrobial agents, 54 (2019) 735-740.

5. M. Bassetti, A. Vena, C. Sepulcri, D.R. Giacobbe, M. Peghin, Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance, Antibiotics, 9 (2020).

6. S. Karakonstantis, E.I. Kritsotakis, A. Gikas, Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems, Infection, 48 (2020) 835-851.

7. R. Lalaoui, E. Javelle, S. Bakour, C. Ubeda, J.M. Rolain, Infections Due to Carbapenem-Resistant Bacteria in Patients With Hematologic Malignancies, Frontiers in microbiology, 11 (2020) 1422.

8. M.J. Lasko, D.P. Nicolau, Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology, Current infectious disease reports, 22 (2020) 6.

9. T.C. Horan, M. Andrus, M.A. Dudeck, CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting, American journal of infection control, 36 (2008) 309-332.

10. S.W. Lam, V. Athans, Clinical and Microbiological Outcomes in Obese Patients Receiving Colistin for Carbapenem-Resistant Gram-Negative Bloodstream Infection, Antimicrobial agents and chemotherapy, 63 (2019).

11. L. Papst, B. Beovic, C. Pulcini, E. Durante-Mangoni, J. Rodriguez-Bano, K.S. Kaye, G.L. Daikos, L. Raka, M. Paul, E.E. Esgap, C.t.s.s.g. the, Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 24 (2018) 1070-1076.

12. E.M. Eichenberger, J.T. Thaden, Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria, Antibiotics, 8 (2019).

13. M.G. McCracken, H.J. Adam, J.M. Blondeau, A.J. Walkty, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, M.R. Mulvey, A. Canadian Antimicrobial Resistance, Canward, Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study, The Journal of antimicrobial chemotherapy, 74 (2019) iv32-iv38.

14. H. Turk Dagi, H. Kus, U. Arslan, I. Tuncer, [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates], Mikrobiyoloji bulteni, 48 (2014) 311-315.

15. B. Liu, Y. Bai, Y. Liu, X. Di, X. Zhang, R. Wang, J. Wang, In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii, Journal of chemotherapy, 27 (2015) 271-276.
16. T. Tangden, C.G. Giske, Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control, Journal of internal medicine, 277 (2015) 501-512.

17. A. Kallen, A. Guh, United States Centers for Disease Control and Prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 17 (2012).

18. F. Chen, C. Shen, X. Pang, Z. Zhang, Y. Deng, L. Han, X. Chen, J. Zhang, Q. Xia, Y. Qian, Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study, Transplant infectious disease : an official journal of the Transplantation Society, 22 (2020) e13199.

19. M. Hamidian, S.J. Nigro, Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii, Microbial genomics, 5 (2019).

20. B. Zheng, Y. Dai, Y. Liu, W. Shi, E. Dai, Y. Han, D. Zheng, Y. Yu, M. Li, Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella pneumoniae Infections in Eastern China, Frontiers in microbiology, 8 (2017) 1061.

21. R. Han, Q. Shi, S. Wu, D. Yin, M. Peng, D. Dong, Y. Zheng, Y. Guo, R. Zhang, F. Hu, G. China Antimicrobial Surveillance Network Study, Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China, Frontiers in cellular and infection microbiology, 10 (2020) 314.

22. Y. Chen, J. Gao, H. Zhang, C. Ying, Spread of the blaOXA-23-Containing Tn2008 in Carbapenem-Resistant Acinetobacter baumannii Isolates Grouped in CC92 from China, Frontiers in microbiology, 8 (2017) 163.

23. X. Zhang, L. Wang, D. Li, P. Li, L. Yuan, F. Yang, Q. Guo, M. Wang, An IncP-2 plasmid sublineage associated with dissemination of blalMP-45 among carbapenem-resistant Pseudomonas aeruginosa, Emerging microbes & infections, 10 (2021) 442-449.

24. Y. Xu, H. Niu, T. Hu, L. Zhang, S. Su, H. He, H. Wang, D. Zhang, High Expression of Metallo-beta-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates of Pseudomonas aeruginosa from Baotou, China, Infection and drug resistance, 13 (2020) 35-43.

Tables

Table 1. In vitro susceptibility test of the antibiotics against CRKP infection in clinical therapy
MEM, Meropenem; SXT, Trimethoprim-Sulfamethoxazole; DOX, Doxycycline; AMK, Amikacin; MFX, Moxifloxacin; NA, not available; MIC, Minimal inhibitory concentration; KB, Kirby-Bauer

**Table 2.** Clinical data for the six CRKP infections treated with antibiotics

| Strain | KB (mm) | MIC values (mg/L) | Biological source of isolation |
|--------|---------|-------------------|------------------------------|
|        | MEM     | SXT               | AMK | DOX | MFX |                      |
| 1      | 6       | >16               | <2  | NA  | NA  | Sputum              |
| 2      | 6       | 2                 | <2  | NA  | NA  | Sputum              |
| 3      | 6       | >16               | <2  | NA  | NA  | Sputum              |
| 4      | 14      | <1                | <2  | NA  | NA  | Urine               |
| 5      | 6       | >16               | >64 | NA  | NA  | Urine               |
| 6      | 6       | >16               | <2  | NA  | NA  | Urine               |

MEM, Meropenem; SXT, Trimethoprim-Sulfamethoxazole; DOX, Doxycycline; AMK, Amikacin; MFX, Moxifloxacin; NA, not available; MIC, Minimal inhibitory concentration; KB, Kirby-Bauer

**Table 3.** In vitro susceptibility test of the antibiotics against CRPA infection in clinical therapy

| Patient | age(y) | sex | infection site | antibiotics | doses | ATD | MO   | CO | AST |
|---------|--------|-----|----------------|--------------|-------|-----|------|----|-----|
| 1       | 73     | F   | lung           | MEM          | 1.0g ivgtt g8h | 8days | E   | Recovered | R  |
| 2       | 46     | M   | lung           | SXT          | 0.96g po q12h | 11days | E   | Improved   | S  |
| 3       | 89     | F   | lung           | DOX          | 0.1g ivgtt g12h | 12days | E   | Recovered   | NA |
| 4       | 71     | M   | Urine          | AMK          | 0.4g ivgtt qd  | 7days   | E   | Recovered   | S  |
| 5       | 81     | M   | Urine          | SXT          | 0.96g po q12h | 38days  | P   | Improved    | R  |
| 6       | 90     | F   | Urine          | MFX          | 0.4g ivgtt qd  | 13days  | P   | Failed      | NA |

Y, Year; F, Femal; M, male; E, Eradication; P, Persistence; MO, Microbiological outcome; CO, Clinical outcome; AST, Antimicrobial susceptibility test; ATD, Antibiotic treatment duration; NA, not available; S, Susceptible; I, Intermediate; R, Resistance

Patient 6: *In vitro* susceptibility test of MFX is not available, but CIP and LVX show resistance.

**Table 3.** *In vitro* susceptibility test of the antibiotics against CRPA infection in clinical therapy
| Strain | MIC values (mg/L) | KB (mm) | Biological source of isolation |
|--------|------------------|---------|-------------------------------|
|        | MFX | CAZ | FEP | TZP | MEM |                  |
| 1      | NA  | 16  | 8   | 64  | 12  | blood            |
| 2      | NA  | >64 | 32  | 64  | 10  | Sputum           |
| 3      | NA  | 4   | 2   | 8   | 12  | Sputum           |
| 4      | NA  | 16  | 8   | 16  | 12  | Urine            |
| 5      | NA  | 32  | 8   | 16  | 10  | Sputum           |
| 6      | NA  | 2   | 4   | <4  | 15  | Sputum           |
| 7      | NA  | 8   | 4   | <4  | 12  | Sputum           |
| 8      | NA  | 8   | 8   | <4  | 13  | Sputum           |
| 9      | NA  | >64 | 32  | >128| 12  | Sputum           |

**Table 4.** Clinical data for the nine *CRPA* infections treated with antibiotics

| Patient | age(y) | sex | infection site | antibiotics | doses       | ATD | MO     | CO | AST     |
|---------|--------|-----|----------------|-------------|-------------|-----|--------|----|---------|
| 1       | 88     | M   | blood          | MFX         | 0.4g ivgtt qd | 14days | E     | Improved | NA |
| 2       | 77     | M   | lung           | MFX         | 0.4g ivgtt qd | 8days  | E     | Recovered | NA |
| 3       | 79     | M   | lung           | CAZ         | 1.5g ivgtt bid | 13days | E     | Recovered | S  |
| 4       | 67     | M   | Urine          | FEP         | 2.0g ivgtt bid | 8days  | E     | Recovered | S  |
| 5       | 78     | M   | lung           | TZP         | 4.5g ivgtt q8h | 5days  | E     | Recovered | S  |
| 6       | 81     | M   | lung           | MEM+MFX     | 0.5g ivg q6h | 11days | P     | Failed    | R+R|
|         |        |     |                |             | +0.4g iv qd   |        |        |       |        |
| 7       | 78     | M   | lung           | TZP         | 4.5g ivgtt q8h | 3days  | E     | Improved | S  |
| 8       | 78     | M   | lung           | CAZ         | 1.5g ivg bid  | 14days | P     | Failed    | S  |
| 9       | 91     | M   | lung           | MFX         | 0.4g ivgtt qd | 9days  | P     | Improved | NA |

Patient 1: *In vitro* susceptibility test of MFX is not available, but CIP and LVX show susceptible.

Patient 2: *In vitro* susceptibility test of MFX is not available, but CIP and LVX show resistance.

Patient 9: *In vitro* susceptibility test of MFX is not available, but CIP and LVX show susceptible.
### Table 5. *In vitro* susceptibility test of the antibiotics against CRAB infection in clinical therapy

| Strain | MIC values (mg/L) | KB (mm) | Biological source of isolation |
|--------|-------------------|---------|-------------------------------|
|        | IPM   | SXT   | LVX | CSL | TGC | MEM | TZP |                      |
| 1      | >16   | 16    | 4   | 11  | 19  | 6   | 6   | Sputum               |
| 2      | >16   | 0.5   | 4   | 15  | 11  | 8   | 8   | Sputum               |
| 3      | >16   | 16    | >8  | 21  | 17  | 8   | 10  | Sputum               |
| 4      | >16   | 1     | >8  | 21  | 15  | 9   | 10  | Sputum               |
| 5      | >16   | 16    | 4   | 14  | 20  | 6   | 8   | Sputum               |
| 6      | >16   | >16   | >8  | 17  | 14  | 6   | 6   | Sputum               |
| 7      | >16   | 16    | >8  | 19  | 16  | 10  | 10  | Sputum               |
| 8      | >16   | 1     | >8  | 15  | 16  | 10  | 6   | Abdominal fluid      |
| 9      | >16   | 1     | 4   | 12  | 17  | 6   | 6   | Sputum               |
| 10     | >16   | <1    | 4   | 15  | 16  | 8   | 6   | Sputum               |
| 11     | >16   | 1     | 4   | 11  | 14  | 6   | 6   | Sputum               |
| 12     | >16   | <1    | 4   | 11  | 18  | 10  | 10  | Sputum               |
| 13     | >16   | >16   | >8  | 18  | 17  | 8   | 10  | Sputum               |
| 14     | >16   | <1    | >8  | 12  | 17  | 7   | 10  | Sputum               |
| 15     | >16   | >16   | >8  | 21  | 16  | 11  | 10  | Sputum               |
| 16     | >16   | >16   | >8  | 8   | 16  | 6   | 9   | Sputum               |
| 17     | >16   | <1    | 4   | 17  | 13  | 6   | 6   | Blood                |
| 18     | >16   | <1    | >8  | 21  | 16  | 8   | 8   | Sputum               |
| 19     | >16   | <1    | 4   | 14  | 16  | 7   | 6   | Sputum               |
| 20     | >16   | >16   | >8  | 15  | 8   | 8   | 9   | Sputum               |
| 21     | >16   | <1    | 4   | 16  | 18  | 8   | 9   | Sputum               |
| 22     | >16   | <1    | 4   | 14  | 16  | 8   | 6   | Sputum               |
| 23     | >16   | >16   | >8  | 21  | 14  | 10  | 9   | Sputum               |
| 24     | >16   | <1    | 4   | 15  | 16  | 10  | 10  | Sputum               |
| 25     | >16   | <1    | 4   | 16  | 16  | 8   | 6   | Sputum               |
| 26     | >16   | <1    | 4   | 10  | 17  | 8   | 6   | Urine                |
| 27     | >16   | >16   | >8  | 21  | 16  | 11  | 9   | Sputum               |
| 28     | >16   | >16   | >8  | 22  | 16  | 8   | 12  | Urine                |
| 29     | >16   | >16   | >8  | 19  | 16  | 6   | 8   | Sputum               |

### Table 6. Clinical data for the 29 CRAB infections treated with antibiotics
| Patient | age(y) | sex | infection site | antibiotics | doses | ATD | MO | CO | AST |
|---------|--------|-----|---------------|-------------|-------|-----|----|----|-----|
| 1       | 61     | M   | lung          | CSL         | 3.0g ivgtt q8h | 9 days | E   | Recovered | R. |
| 2       | 71     | M   | lung          | CSL         | 3.0g ivgtt q8h | 19 days | P   | Failed     | R. |
| 3       | 65     | M   | lung          | CSL         | 1.5g ivgtt q8h | 10 days | E   | Recovered | M  |
| 4       | 90     | M   | lung          | TZP         | 4.5g ivgtt q8h | 19 days | E   | Improved   | R. |
| 5       | 76     | M   | lung          | IMP/CS      | 1.0g ivgtt q8h | 4 days  | E   | Recovered | R. |
| 6       | 91     | M   | lung          | CSL         | 3.0g ivgtt q8h | 10 days | P   | Improved   | M  |
| 7       | 84     | M   | lung          | TZP         | 4.5g ivgtt q8h | 2 days  | P   | Failed     | R. |
| 8       | 35     | M   | Abdominal cavity | CSL=TGC | 3.0g ivgtt q12h+50mg ivgtt qd | 8 days  | P   | Improved | R+S |
| 9       | 88     | F   | lung          | TZP         | 4.5g ivgtt q8h | 11 days | E   | Recovered | R. |
| 10      | 89     | F   | lung          | IMP/CS=TGC | 1.0g ivgtt q8h+50mg ivgtt q12h | 17 days | E   | Improved | R+S |
| 11      | 91     | F   | lung          | TZP         | 4.5g ivgtt q8h | 9 days  | P   | Failed     | R. |
| 12      | 88     | M   | lung          | SXT         | 0.96g po q12h | 6 days  | P   | Failed     | S  |
| 13      | 68     | M   | lung          | CSL         | 3.0g ivgtt q8h | 14 days | P   | Failed     | M  |
| 14      | 71     | M   | lung          | IMP/CS=TGC | 1.0g ivgtt q8h+50mg ivgtt q12h | 15 days | P   | Failed     | R+S |
| 15      | 02     | M   | lung          | CSL         | 3.0g ivgtt q12h | 10 days | R   | Improved   | S  |
| 16      | 83     | M   | lung          | CSL=TGC     | 3.0g ivgtt q8h+50mg ivgtt q12h | 14 days | P   | Failed     | R+S |
| 17      | 80     | F   | Blood         | CSL         | 3.0g ivgtt q8h | 7 days  | E   | Recovered | M  |
| 18      | 47     | M   | lung          | CSL         | 3.0g ivgtt q8h | 6 days  | E   | Recovered | S  |
| 19      | 71     | M   | lung          | CSL=TGC     | 3.0g ivgtt q12h+50mg ivgtt q12h | 9 days  | E   | Recovered | S+S |
| 20      | 88     | M   | lung          | CSL=TGC     | 3.0g ivgtt q12h+50mg ivgtt q12h | 8 days  | P   | Failed     | R+R |
| 21      | 72     | M   | lung          | CSL=TGC     | 3.0g ivgtt q8h+50mg ivgtt q12h | 8 days  | P   | Improved | M+S |
| 22      | 65     | M   | lung          | MEM         | 1.0g ivgtt q8h | 10 days | P   | Failed     | R  |
| 23      | 66     | F   | lung          | CSL         | 1.5g ivgtt q8h | 7 days  | E   | Recovered | S  |
| 24      | 56     | M   | lung          | CSL         | 3.0g ivgtt q8h | 10 days | E   | Recovered | R  |
| 25      | 79     | F   | lung          | MEM=TGC     | 1.0g ivgtt q8h+50mg ivgtt q12h | 11 days | E   | Recovered | R+S |
| 26      | 71     | F   | Urine tract   | SXT+LUX     | 0.96g po tid+500mg ivgtt qd | 12 days | E   | Recovered | S+M |
| 27      | 64     | M   | lung          | CSL         | 3.0g ivgtt q12h | 5 days  | P   | Improved | S  |
| 28      | 74     | F   | Urine tract   | CSL         | 3.0g ivgtt q12h | 6 days  | P   | Failed     | S  |
| 29      | 36     | M   | lung          | CSL=TGC     | 3.0g ivgtt q8h+50mg ivgtt q12h | 8 days  | P   | Failed | M+S |

CS, Cilastatin sodium.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTable.docx